Professor Frank Gannon - Chairman
Professor Frank Gannon is the Director and CEO of the QIMR Berghofer Medical Research Institute. He joined QIMR Berghofer in January 2011, having been Director General and board member of Science Foundation Ireland (SFI) since 2007.
He obtained his PhD from the University of Leicester, England in 1973 and worked subsequently in the USA, France, Ireland and Germany where he was Executive Director of the European Molecular Biology Organisation (EMBO) from 1994-2007. He has been on the Scientific Advisory Boards of multiple institutes and Industries world-wide.
His major research interest is the regulation of gene expression by the oestrogen receptor, which plays a major role in breast and endometrial cancer. These studies have provided leads to novel treatments or therapeutic approaches to these and other cancers and have resulted in the establishment of two spin-off companies.
Donna Hancock - Non-Executive Director
Donna Hancock is the Chief Operating Officer, Secretary to QIMR Berghofer Council, and heads the Institute’s Support Division. She holds a Bachelor of Commerce from Newcastle University and a Masters in Business Administration from the University of Melbourne.
She has an extensive background in finance, business planning, business development, systems development and commercial management. Prior to joining QIMR Berghofer, Donna worked for more than 20 years as a senior executive with BHP Billiton.
Donna is a director of Q-Pharm Pty Ltd, a member of the Australia India Business Council Women’s Executive Committee, a former member of the Medical Board of Australia (Qld Registrations Committee) and a former member of the Pharmacists Board of Queensland.
Professor Geoff Hill - Non-Executive Director
Professor Geoff Hill is a medical graduate of the University of Auckland and Haematologist, training in New Zealand, The Dana Farber Cancer Institute, and Harvard Medical School in Boston. He is a NHMRC Senior Principal Research Fellow and his immunology laboratory focuses on the interactions between cytokines, antigen presenting cells and regulatory cells during transplantation.
Prof Hill was the 2005 Queenslander of the Year and recipient of the Transplantation Society of Australia and New Zealand 2009 Ian McKenzie Award for excellence within basic and clinical research in the transplant field. He was also awarded a Queensland Health Senior Clinical Research Fellowship in 2010 to translate new therapies into clinic practice; and in 2011 received a prestigious five year NHMRC Australia Fellowship. In 2014 he was awarded the inaugural Translational Research Institute National Prize for research improving health outcomes for patients. In 2015 he was elected to the Australian Academy of Health and Medical Research.
Mr Chris Coyne – Non-Executive Director
Mr Coyne is Deputy Chair of the QIMR Berghofer Council
Mr Coyne is a solicitor of the Supreme Court of Queensland and an accredited specialist in the field of Commercial Litigation, specialising in insurance law, health law, corporate governance and risk management. Following his admission as a solicitor in 1979 he practised law in Brisbane and was a partner in the national law firm Clayton Utz from 1984 to 2004.
Mr Coyne now practices on his own account. He is a member of the Council of the Queensland Law Society. Mr Coyne is a Director of the Incorporated Council of Law Reporting for the State of Queensland, past president Medico-Legal Society of Queensland and Australian Insurance Law Association and former legal member Australian Health Ethics Committee.
Mr Coyne is a member of the QIMR Berghofer Executive Employment and Remuneration Committee and a Director of the Q-Pharm Pty Ltd Board (a wholly-owned subsidiary of QIMR Berghofer).
Michael Creevey – Non-Executive Director
Michael has a technical background with degrees in computer science and electrical engineering. Following university he founded and sold various tech start-ups. After 10 years he made a conscious move into the biotechnology sector eventually becoming a General Manager of Research Support and Governance at the QIMR Berghofer Medical Research Institute. Following a short period as Q-Pharm's interim CEO, Michael is now moving into establishing a new spin-out company in digital health.